Loading…

Genetic ablation of IRAK4 kinase activity inhibits vascular lesion formation

Inflammation is critically involved in atherogenesis. Signaling from innate immunity receptors TLR2 and 4, IL-1 and IL-18 is mediated by MyD88 and further by interleukin-1 receptor activated kinases (IRAK) 4 and 1. We hypothesized that IRAK4 kinase activity is critical for development of atheroscler...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2008-03, Vol.367 (3), p.642-648
Main Authors: Rekhter, Mark, Staschke, Kirk, Estridge, Thomas, Rutherford, Pamela, Jackson, Nancy, Gifford-Moore, Donetta, Foxworthy, Patricia, Reidy, Charles, Huang, Xiao-di, Kalbfleisch, Michael, Hui, Kwan, Kuo, Ming-Shang, Gilmour, Raymond, Vlahos, Chris J.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inflammation is critically involved in atherogenesis. Signaling from innate immunity receptors TLR2 and 4, IL-1 and IL-18 is mediated by MyD88 and further by interleukin-1 receptor activated kinases (IRAK) 4 and 1. We hypothesized that IRAK4 kinase activity is critical for development of atherosclerosis. IRAK4 kinase-inactive knock-in mouse was crossed with the ApoE−/− mouse. Lesion development was stimulated by carotid ligation. IRAK4 functional deficiency was associated with down-regulation of several pro-inflammatory genes, inhibition of macrophage infiltration, smooth muscle cell and lipid accumulation in vascular lesions. Reduction of plaque size and inhibition of outward remodeling were also observed. Similar effects were observed when ApoE−/− mice subjected to carotid ligation were treated with recombinant IL-1 receptor antagonist thereby validating the model in the relevant pathway context. Thus, IRAK4 functional deficiency inhibits vascular lesion formation in ApoE−/− mice, which further unravels mechanisms of vascular inflammation and identifies IRAK4 as a potential therapeutic target.
ISSN:0006-291X
1090-2104
DOI:10.1016/j.bbrc.2007.12.186